Environmental

APYX’s R&D intensity of 5.7% of revenue suggests some product and process investment, but peers with larger medtech platforms typically sustain broader environmental innovation programs.

The company’s capital-light environmental footprint is likely less material than manufacturing-heavy peers, yet the absence of disclosed emissions or energy metrics limits evidence of superior environmental management.

Negative net debt to EBITDA indicates low balance-sheet pressure, which can support longer-horizon environmental compliance spending more easily than highly levered peers.

No filing-based evidence provided here indicates formal climate targets, renewable-energy commitments, or supply-chain decarbonization programs, leaving APYX’s environmental positioning less demonstrably advanced than peers.

Social

APYX’s R&D spending supports product development and can indirectly improve patient outcomes, but peers with larger clinical and regulatory infrastructures often show stronger social disclosure and governance around safety.

Stock-based compensation at 3.2% of revenue suggests employee alignment without appearing excessive, which is broadly comparable to mid-cap healthcare peers.

The provided metrics do not show workforce turnover, diversity, or training disclosure, so APYX’s social positioning remains harder to verify than peers with more extensive reporting.

As a medical technology company, product quality and patient safety are material social factors, but the available data do not demonstrate a clear peer-leading advantage on these dimensions.

Governance

Debt-to-equity of 3.7x indicates a more leveraged capital structure than many small-cap medtech peers, which can constrain governance flexibility and heighten creditor oversight.

Negative net debt to EBITDA suggests liquidity is not currently strained, partially offsetting leverage concerns and reducing near-term governance risk versus more distressed peers.

Stock-based compensation at 3.2% of revenue is manageable, but without board independence, audit, or ownership disclosures, governance quality cannot be shown to exceed peers.

The limited disclosure set prevents evidence of stronger controls, shareholder protections, or controversy management, leaving APYX’s governance profile broadly average rather than leading.

Overall Score

APYX appears broadly average versus peers, with modestly supportive R&D and liquidity characteristics offset by limited ESG disclosure and a more leveraged capital structure.

Score Driver: Limited Disclosure Across Material ESG Dimensions Prevents APYX From Demonstrating A Clear Peer-Leading Position.